Chinese Traditional and Herbal Drugs
|
2025, 56(21): 7690-7699
Material basis of Kaixinsan in treating depression-Alzheimer’s disease comorbidity based on UPLC-Orbitrap-MS/MS, GNPS molecular networking, and network pharmacology
Full
Affiliations
doi: 10.7501/j.issn.0253-2670.2025.21.004
Outline
Objective To establish a research strategy for the material basis of traditional Chinese medicine treatment of comorbidities based on high-resolution mass spectrometry, the global natural products social molecular networking (GNPS), and network pharmacology, and conduct a systematic analysis of the material basis of Kaixinsan (开心散) treatment for depression and Alzheimer’s disease. Methods First, ultra-high-performance liquid chromatography-orbitrap tandem mass spectrometry (UPLC-Orbitrap-MS/MS) was used to perform non-targeted secondary mass spectrometry analysis on the extracts of Kaixinsan and its plasma and brain tissue exposure samples. Then, using the GNPS platform, molecular networks were constructed based on the mass spectrometry data obtained from the Kaixinsan extract and plasma samples. Combining the precise mass numbers, retention times, fragmentation information, and mass spectrometry fragmentation patterns of the compounds, the plasma exposure components of Kaixinsan were rapidly identified. Subsequently, based on the plasma exposure components, combined with the high-resolution mass spectrometry data from the brain tissue samples, the brain-penetrating components of Kaixinsan were identified. Finally, the material basis for treatment of depression-Alzheimer’s disease comorbidity by the Kaixinsan was explored by combining brain tissue exposure components and network pharmacology techniques. Results A total of 34 components exposed to Kaixinsan were identified in plasma, and a total of 21 components exposed to Kaixinsan were identified in brain tissue. A total of 19 components with therapeutic activity for depression-Alzheimer’s disease comorbidity were screened from Kaixinsan, including 9 saponins, 9 oligosaccharide esters, and 1 xanthone. Conclusion This study established a new strategy for rapidly identifying the material basis of concomitant diseases in traditional Chinese medicine, providing methodological support for research on treatment of different diseases with the same treatment in traditional Chinese medicine. It also provided data support for explaining the material basis of the treatment of depression and Alzheimer’s disease concomitant diseases with Kaixinsan and its clinical application.
Kaixinsan
/
UPLC-Orbitrap-MS/MS
/
GNPS molecular networking
/
network pharmacology
/
depression-Alzheimer’s comorbidity
/
material basis
安若凡, 高艳华, 毛樱潞, 万会花, 孙伟, 郑颖, 杨维.
基于UPLC-Orbitrap-MS/MS、GNPS分子网络、网络药理学的开心散治疗抑郁症-阿尔茨海默病共病物质基础研究.
中草药,
2025
, 56
(21)
: 7690
-7699
.
DOI: 10.7501/j.issn.0253-2670.2025.21.004
AN Ruofan, GAO Yanhua, MAO Yinglu, WAN Huihua, SUN Wei, ZHENG Ying, YANG Wei.
Material basis of Kaixinsan in treating depression-Alzheimer’s disease comorbidity based on UPLC-Orbitrap-MS/MS, GNPS molecular networking, and network pharmacology[J].
Chinese Traditional and Herbal Drugs,
2025
, 56
(21)
: 7690
-7699
.
DOI: 10.7501/j.issn.0253-2670.2025.21.004
Year 2025 volume 56 Issue 21
57
11
Cite this Article
BibTeX
Article Info
doi: 10.7501/j.issn.0253-2670.2025.21.004
- Receive Date:2025-07-09
- Online Date:2026-11-13